4 active not recruiting, 2 unknown, 1 terminated. 5 Phase 2, 3 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Active not recruiting 3, Unknown 2 |
| Phase 1 | 3 | Active not recruiting 1, Terminated 1, Unknown 1 |
| Phase 3 | 1 | Active not recruiting 1 |
Follow CanariaBio Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Oregovomab Plus Chemotherapy in Neo-adjuvant Setting in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Oregovomab, Paclitaxel, Carboplatin - Ovarian Neoplasm Epithelial, Ovarian Cancer | Phase 2 | Active not recruiting | CanariaBio Inc. | 88 | 2023-02-07 | 2026-04-01 |
| A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer. Oregovomab, Niraparib - Recurrent Ovarian Cancer, Recurrent Epithelial Cancer of Ovary | Phase 2 | Active not recruiting | CanariaBio Inc. | 10 | 2022-07-25 | 2026-04-03 |
| Oregovomab and PLD in PARP Inhibitor Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients Not Candidate for Platinum Retreatment Orevogomab+PLD, Orevogomab+Paclitaxel - PARP Inhibitor Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients Not Candidate for Platinum Retreatment | Phase 2 | Unknown | Yonsei University | 56 | 2022-07-05 | 2023-05-24 |
| Oregovomab in Combination With Bevacizumab Plus Chemo in BRCA Wild Type Platinum Sensitive Recurrent Ovarian Cancer Oregovomab, Bevacizumab, Paclitaxel - Ovarian Cancer by FIGO Stage, Ovarian Cancer Stage III | Phase 1 / Phase 2 | Active not recruiting | CanariaBio Inc. | 54 | 2021-03-17 | 2026-04-06 |
| Clinical Trial of Chemotherapy, Oregovomab and Nivolumab in Patients With Epithelial Cancer of Ovarian, Tubal or Peritoneal Origin Oregovomab, Nivolumab, Chemotherapy - Epithelial Ovarian Cancer | Phase 1 / Phase 2 | Unknown | National Cancer Centre, Singapore | 31 | 2020-10-07 | 2021-12-01 |
| Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery Oregovomab, Paclitaxel, Carboplatin - Carcinoma, Ovarian Epithelial, Ovarian Neoplasms | Phase 3 | Active not recruiting | CanariaBio Inc. | 615 | 2020-08-25 | 2026-04-01 |
| The Safety and Antitumor Activity of the Combination of Oregovomab and Hiltonol in Recurrent Advanced Ovarian Cancer Oregovomab, Poly ICLC - Cancer of Ovary, Neoplasms, Ovarian | Phase 1 | Terminated | CanariaBio Inc. | 10 | 2017-05-30 | 2020-12-22 |
Ovarian Neoplasms (5) · Carcinoma, Ovarian Epithelial (3) · Fallopian Tube Neoplasms (3) · Peritoneal Neoplasms (1)
oregovomab (6) · Carboplatin (3) · Paclitaxel (3) · Bevacizumab (1) · Cisplatin (1) · Drug Therapy (1) · Nivolumab (1) · niraparib (1) · poly ICLC (1)
South Korea (3) · United States (3) · India (2) · Argentina (1) · Belgium (1) · Brazil (1) · Canada (1) · Chile (1) · Czechia (1) · Hungary (1) · Italy (1) · Mexico (1) · Singapore (1) · Spain (1) · Taiwan (1)
Sunil Gupta, MD, FRCPC (2) · Christopher Nicodemus, MD FACP (1) · Dr Jung KH, MD (1) · Jack Chan, MD (1) · Jada Srinivasa Rao, PhD (1) · Jung-Yun Lee (1)